H.C. Wainwright Raises Annovis Bio Stock Target Amid Promising Phase 3 Results
Friday, 12 July 2024, 08:40
H.C. Wainwright Raises Annovis Bio Stock Target
H.C. Wainwright, a prominent financial firm, has recently raised the target price for shares of Annovis Bio.
Positive Phase 3 Outcomes
The increase in target price comes in light of the highly encouraging results from the Phase 3 trials conducted by Annovis Bio.
Investors are optimistic about the growth prospects of the company based on these promising outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.